223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer

Jiaqiong Wang; Russ Kuker; Aldo Serafini

doi:10.1097/RLU.0000000000003168

²²³Ra-Dichloride Response Evaluation Using ¹⁸F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer

Jiaqiong Wang, Russ Kuker, Aldo Serafini

Radiology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.

Original language	English (US)
Pages (from-to)	e486-e488
Journal	Clinical nuclear medicine
Volume	45
Issue number	11
DOIs	https://doi.org/10.1097/RLU.0000000000003168
State	Published - Nov 1 2020

Keywords

F-fluciclovine PET/CT
Ra-dichloride
Tc-MDP
bone scan
prostate cancer

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000003168

Fingerprint Dive into the research topics of '<sup>223</sup>Ra-Dichloride Response Evaluation Using <sup>18</sup>F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this

@article{86ae1b26c1a64b6aad79a6d32090cbdf,

title = "223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer",

abstract = "A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued. ",

keywords = "F-fluciclovine PET/CT, Ra-dichloride, Tc-MDP, bone scan, prostate cancer",

author = "Jiaqiong Wang and Russ Kuker and Aldo Serafini",

year = "2020",

month = nov,

day = "1",

doi = "10.1097/RLU.0000000000003168",

language = "English (US)",

volume = "45",

pages = "e486--e488",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - 223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer

AU - Wang, Jiaqiong

AU - Kuker, Russ

AU - Serafini, Aldo

PY - 2020/11/1

Y1 - 2020/11/1

N2 - A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.

AB - A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.

KW - F-fluciclovine PET/CT

KW - Ra-dichloride

KW - Tc-MDP

KW - bone scan

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85092680092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092680092&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000003168

DO - 10.1097/RLU.0000000000003168

M3 - Article

C2 - 32657864

AN - SCOPUS:85092680092

VL - 45

SP - e486-e488

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 11

ER -